Table 1.
Active large Phase I–III trials of PARP inhibitors in patients with TNBC
| ClinicalTrials.gov identifier | Population | Therapy | Phase | Status |
|---|---|---|---|---|
| NCT02338622 | Advanced TNBC | Olaparib (AZD2281) + AZD5363 (AKT inhibitor) | I | Recruiting44 |
| NCT00707707 | mTNBC | AZD2281 + paclitaxel | I | Active, not recruiting45 |
| NCT01074970 | TNBC with BRCA1/2 mutations | Cisplatin + rucaparib + preoperative chemotherapy | II | Active, not recruiting46 |
| NCT02032277 | Early TNBC | Carboplatin-based NAC + veliparib/placebo | III | Recruiting47 |
| NCT01204125 | TNBC | Iniparib (SAR2405550-BSI-201) + paclitaxel | II | Recruiting48 |
| NCT00938652 | mTNBC | BSI-201 + gemcitabine/carboplatin | III | Completed49 |
Note: Recent preclinical and clinical data indicate that iniparib does not possess characteristics typical of PARP inhibitor class.
Abbreviations: BRCA, breast cancer susceptibility protein; NAC, neoadjuvant chemotherapy; PARP, poly(ADP-ribose) polymerase; TNBC, triple-negative breast cancer; mTNBC, metastatic TNBC.